Search research articles
Contact Us
Filters
Showing results (41-50 of 53) with videos related to
Page
of 6
Sort By:
Oncotarget
|
March 24, 2016
A phase I study of indoximod in patients with advanced malignancies
Hatem H Soliman, Susan E Minton, Hyo Sook Han, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
March 27, 2021
Preclinical evaluation of [<sup>225</sup>Ac]Ac-DOTA-TATE for treatment of lung neuroendocrine neoplasms
Narges K Tafreshi, Darpan N Pandya, Christopher J Tichacek, et al.
Patient Education and Counseling
|
December 3, 2017
Patient, caregiver and physician perspectives on participating in a thoracic rapid tissue donation program
Gwendolyn P Quinn, Rebecca D Pentz, Teresita Muñoz-Antonia, et al.
The Lancet. Oncology
|
August 26, 2014
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study
Shirish M Gadgeel, Leena Gandhi, Gregory J Riely, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 7, 2022
Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non-Small Cell Lung Cancer
Alberto A Chiappori, Ben Creelan, Tawee Tanvetyanon, et al.
Journal for Immunotherapy of Cancer
|
October 27, 2022
First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors
Omid Hamid, Alberto A Chiappori, John A Thompson, et al.
Oncotarget
|
October 21, 2016
Early2 factor (E2F) deregulation is a prognostic and predictive biomarker in lung adenocarcinoma
Lu Chen, Courtney A Kurtyka, Eric A Welsh, et al.
Clinical Lung Cancer
|
October 1, 2016
Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations
Natasha B Leighl, Naiyer A Rizvi, Lopes Gilberto de Lima, et al.
JAMA Oncology
|
September 2, 2021
Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial
Leora Horn, Ziping Wang, Gang Wu, et al.
Cancer Medicine
|
November 21, 2019
A community-based lung cancer rapid tissue donation protocol provides high-quality drug-resistant specimens for proteogenomic analyses
Theresa A Boyle, Gwendolyn P Quinn, Matthew B Schabath, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 53) with videos related to
Sort By:
Page
of 6
Oncotarget
|
March 24, 2016
A phase I study of indoximod in patients with advanced malignancies
Hatem H Soliman, Susan E Minton, Hyo Sook Han, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
March 27, 2021
Preclinical evaluation of [<sup>225</sup>Ac]Ac-DOTA-TATE for treatment of lung neuroendocrine neoplasms
Narges K Tafreshi, Darpan N Pandya, Christopher J Tichacek, et al.
Patient Education and Counseling
|
December 3, 2017
Patient, caregiver and physician perspectives on participating in a thoracic rapid tissue donation program
Gwendolyn P Quinn, Rebecca D Pentz, Teresita Muñoz-Antonia, et al.
The Lancet. Oncology
|
August 26, 2014
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study
Shirish M Gadgeel, Leena Gandhi, Gregory J Riely, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 7, 2022
Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non-Small Cell Lung Cancer
Alberto A Chiappori, Ben Creelan, Tawee Tanvetyanon, et al.
Journal for Immunotherapy of Cancer
|
October 27, 2022
First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors
Omid Hamid, Alberto A Chiappori, John A Thompson, et al.
Oncotarget
|
October 21, 2016
Early2 factor (E2F) deregulation is a prognostic and predictive biomarker in lung adenocarcinoma
Lu Chen, Courtney A Kurtyka, Eric A Welsh, et al.
Clinical Lung Cancer
|
October 1, 2016
Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations
Natasha B Leighl, Naiyer A Rizvi, Lopes Gilberto de Lima, et al.
JAMA Oncology
|
September 2, 2021
Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial
Leora Horn, Ziping Wang, Gang Wu, et al.
Cancer Medicine
|
November 21, 2019
A community-based lung cancer rapid tissue donation protocol provides high-quality drug-resistant specimens for proteogenomic analyses
Theresa A Boyle, Gwendolyn P Quinn, Matthew B Schabath, et al.
Page
of 6